Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 150 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; light magnesium oxide; sodium stearylfumarate; indigo carmine aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 88 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; light magnesium oxide; sodium starch glycollate; sodium stearylfumarate; indigo carmine aluminium lake; tartrazine aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 137 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; light magnesium oxide; microcrystalline cellulose; sodium stearylfumarate; brilliant blue fcf aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 88 microgram - tablet, uncoated - excipient ingredients: sodium stearylfumarate; sodium starch glycollate; light magnesium oxide; microcrystalline cellulose; indigo carmine aluminium lake; tartrazine aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 200 microgram - tablet, uncoated - excipient ingredients: light magnesium oxide; sodium stearylfumarate; microcrystalline cellulose; sodium starch glycollate; allura red ac aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 112 microgram - tablet, uncoated - excipient ingredients: light magnesium oxide; sodium stearylfumarate; microcrystalline cellulose; sodium starch glycollate; allura red ac aluminium lake; carmine - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 75 microgram - tablet, uncoated - excipient ingredients: light magnesium oxide; sodium stearylfumarate; sodium starch glycollate; microcrystalline cellulose; allura red ac aluminium lake; indigo carmine aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 50 microgram - tablet, uncoated - excipient ingredients: sodium stearylfumarate; microcrystalline cellulose; light magnesium oxide; sodium starch glycollate - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - mycophenolate sodium, quantity: 384.7 mg (equivalent: mycophenolic acid, qty 360 mg) - tablet, enteric coated - excipient ingredients: purified talc; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; povidone; titanium dioxide; iron oxide yellow; iron oxide red; triethyl citrate; sodium lauryl sulfate; sodium bicarbonate; methacrylic acid copolymer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - mycophenolic acid intas tablets are indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.,mycophenolic acid intas tablets are indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis.,this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - mycophenolate sodium, quantity: 192.35 mg (equivalent: mycophenolic acid, qty 180 mg) - tablet, enteric coated - excipient ingredients: croscarmellose sodium; magnesium stearate; purified talc; colloidal anhydrous silica; povidone; microcrystalline cellulose; titanium dioxide; iron oxide yellow; triethyl citrate; sodium lauryl sulfate; indigo carmine aluminium lake; sodium bicarbonate; methacrylic acid copolymer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - mycophenolic acid intas tablets are indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.,mycophenolic acid intas tablets are indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis.,this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.